The role of active vaccination in cancer immunotherapy: Lessons from clinical trials

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 15-22

  Kissick, Haydn T ^a   Sanda, Martin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MELANOMA ANTIGEN 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; T LYMPHOCYTE RECEPTOR; BLOCKING ANTIBODY; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE FREQUENCY; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; QUALITY IMPROVEMENT; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION;

EID: 84936112179     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.05.004     Document Type: Review

References (68)

1. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
2. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
3. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
4. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
5. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
6. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
7. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
8. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
9. Hinrichs C.S., Rosenberg S.A. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014, 257:56-71.
10. Barrett D.M., Singh N., Porter D.L., Grupp S.A., June C.H. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014, 65:333-347.
11. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
12. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
13. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014, 371:1507-1517.
14. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
15. Kissick H.T., Sanda M.G., Dunn L.K., Arredouani M.S. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 2014, 9:e93231.
16. Kissick H.T., Sanda M.G., Dunn L.K., Arredouani M.S. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol Immunother 2013, 62:1831-1840.
17. Vigneron N., Stroobant V., Van den Eynde B.J., van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013, 13:15.
18. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., Provost N., Frohlich M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
19. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
20. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., Verjee S.S., Jones L.A., Hershberg R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
21. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
22. Melero I., Gaudernack G., Gerritsen W., Huber C., Parmiani G., Scholl S., Thatcher N., Wagstaff J., Zielinski C., Faulkner I., et al. The rapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014, 11:509-524.
23. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., Lopez-Brea M., Vanakesa T., Jassem J., Kalofonos H., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403.
24. ClinicalTrials.gov. National Library of Medicine (US). 2000-2015. Available from: , NLM identifier: . ctgov:NCT00004451.
25. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., Suciu S., Kruit W.H., Eggermont A.M., Vansteenkiste J., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013, 31:2388-2395.
26. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
27. Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., Valone F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.
28. ClinicalTrials.gov. National Library of Medicine (US) 2000-2015. Available from: , NLM identifier: . ctgov:NCT00796445.
29. Ozao-Choy J., Lee D.J., Faries M.B. Melanoma vaccines: mixed past, promising future. Surg Clin North Am 2014, 94:1017-1030. viii.
30. Sosman J.A., Carrillo C., Urba W.J., Flaherty L., Atkins M.B., Clark J.I., Dutcher J., Margolin K.A., Mier J., Gollob J., et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008, 26:2292-2298.
31. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
32. Alanio C., Lemaitre F., Law H.K., Hasan M., Albert M.L. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 2010, 115:3718-3725.
33. Pittet M.J., Valmori D., Dunbar P.R., Speiser D.E., Lienard D., Lejeune F., Fleischhauer K., Cerundolo V., Cerottini J.C., Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999, 190:705-715.
34. Enk A.H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997, 73:309-316.
35. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
36. Gabrilovich D.I., Nadaf S., Corak J., Berzofsky J.A., Carbone D.P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996, 170:111-119.
37. Scarlett U.K., Rutkowski M.R., Rauwerdink A.M., Fields J., Escovar-Fadul X., Baird J., Cubillos-Ruiz J.R., Jacobs A.C., Gonzalez J.L., Weaver J., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012, 209:495-506.
38. Fourcade J., Kudela P., Sun Z., Shen H., Land S.R., Lenzner D., Guillaume P., Luescher I.F., Sander C., Ferrone S., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-5249.
39. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
40. Akondy R.S., Monson N.D., Miller J.D., Edupuganti S., Teuwen D., Wu H., Quyyumi F., Garg S., Altman J.D., Del Rio C., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009, 183:7919-7930.
41. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., Murali-Krishna K., Mahar P.L., Edupuganti S., Lalor S., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
42. Westermann J., Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?. Immunol Today 1990, 11:406-410.
43. Gulley J.L., Madan R.A., Tsang K.Y., Jochems C., Marte J.L., Farsaci B., Tucker J.A., Hodge J.W., Liewehr D.J., Steinberg S.M., et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014, 2:133-141.
44. Kaufman H.L., Wang W., Manola J., DiPaola R.S., Ko Y.J., Sweeney C., Whiteside T.L., Schlom J., Wilding G., Weiner L.M. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004, 22:2122-2132.
45. Fong L., Carroll P., Weinberg V., Chan S., Lewis J., Corman J., Amling C.L., Stephenson R.A., Simko J., Sheikh N.A., et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014, 106.
46. Madan R.A., Mohebtash M., Arlen P.M., Vergati M., Rauckhorst M., Steinberg S.M., Tsang K.Y., Poole D.J., Parnes H.L., Wright J.J., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:501-508.
47. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., Gall H.E., Harding T.C., Jooss K., Lowy I., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509-517.
48. Butts C., Socinski M.A., Mitchell P.L., Thatcher N., Havel L., Krzakowski M., Nawrocki S., Ciuleanu T.E., Bosquee L., Trigo J.M., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:59-68.
49. Golden E.B., Pellicciotta I., Demaria S., Barcellos-Hoff M.H., Formenti S.C. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012, 2:88.
50. Moskophidis D., Lechner F., Pircher H., Zinkernagel R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
51. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998, 188:2205-2213.
52. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
53. Ghebeh H., Barhoush E., Tulbah A., Elkum N., Al-Tweigeri T., Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008, 8:57.
54. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014, 124:2246-2259.
55. Piao Y.R., Jin Z.H., Yuan K.C., Jin X.S. Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol 2014, 35:11409-11414.
56. Sfanos K.S., Bruno T.C., Meeker A.K., De Marzo A.M., Isaacs W.B., Drake C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69:1694-1703.
57. Wu X., Zhang H., Xing Q., Cui J., Li J., Li Y., Tan Y., Wang S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer 2014, 111:1391-1399.
58. Grosso J.F., Goldberg M.V., Getnet D., Bruno T.C., Yen H.R., Pyle K.J., Hipkiss E., Vignali D.A., Pardoll D.M., Drake C.G. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009, 182:6659-6669.
59. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392.
60. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
61. Workman C.J., Cauley L.S., Kim I.J., Blackman M.A., Woodland D.L., Vignali D.A. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004, 172:5450-5455.
62. Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S., et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014, 12:97.
63. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009, 83:9122-9130.
64. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008, 205:2763-2779.
65. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
66. Fourcade J., Sun Z., Pagliano O., Chauvin J.M., Sander C., Janjic B., Tarhini A.A., Tawbi H.A., Kirkwood J.M., Moschos S., et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res 2014, 74:1045-1055.
67. Ibrahim N.K., Murray J.L., Zhou D., Mittendorf E.A., Sample D., Tautchin M., Miles D. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 2013, 4:577-584.
68. Miles D., Roche H., Martin M., Perren T.J., Cameron D.A., Glaspy J., Dodwell D., Parker J., Mayordomo J., Tres A., et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011, 16:1092-1100.